Skip to main navigation

Investor Relations

Home
Investors & Media
Contact Us
Careers

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Overview
News / Events
Financial
- Annual Reports & Proxies
- Financial Results
Stock
SEC Filings
- All SEC Filings
Corporate Governance

Press Coverage

Year

Jan 12, 2023

BioXcel reports data from study of rare prostate cancer therapy

Jan 11, 2023

BioXcel, keeping cards close to its chest, teases phase 2 Keytruda combination trial data drop

Jan 11, 2023

BioXcel Spinout Posts Promising Results in Rare Prostate Cancer

Jan 06, 2023

Genetics, Alzheimer's And AI — Why 2023 Could Be The Year For Biotech Stocks

Site - Investor Tools

Print Page

Tear Sheet

Email Alerts

RSS Feeds

Contacts

Search

About Us
Our Products
Our Pipeline
Our Science
Patients & Advocacy

Home
Investors & Media
Contact Us
Careers

Copyright © 2023 BioXcel Therapeutics, Inc. All Rights Reserved.

Privacy Policy
Disclaimer
Sitemap